Principles for designing future regimens for multidrug-resistant tuberculosis-Reference-Cited by-同舟云学术

Principles for designing future regimens for multidrug-resistant tuberculosis

Published:2013-10-25 Issue:1 Volume:92 Page:68-74
ISSN:0042-9686
Container-title:Bulletin of the World Health Organization
language:
Short-container-title:Bull. World Health Organ.

Author:

Brigden Grania¹,Nyang’wa Bern-Thomas²,du Cros Philipp²,Varaine Francis³,Hughes Jennifer⁴,Rich Michael⁵,Horsburgh C Robert⁶,Mitnick Carole D⁷,Nuermberger Eric⁸,McIlleron Helen⁹,Phillips Patrick PJ¹⁰,Balasegaram Manica¹

Affiliation:

1. Access Campaign, Médecins Sans Frontières, 78 Rue de Lausanne, PO Box 116, Geneva, CH1211, Switzerland.

2. Médecins Sans Frontières, London, England.

3. Médecins Sans Frontières, Paris, France.

4. Médecins Sans Frontières, Cape Town, South Africa.

5. Partners in Health, Boston, United States of America (USA).

6. Boston University School of Public Health, Boston, USA.

7. Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA.

8. Center for Tuberculosis Research, Johns Hopkins University, Baltimore, USA.

9. Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.

10. Medical Research Council Clinical Trials Unit, London, England.

Publisher

WHO Press

Subject

Public Health, Environmental and Occupational Health

Reference30 articles.

1. World Health Organization [Internet]. WHO global tuberculosis report 2012. Geneva: WHO; 2012. Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf [accessed 29 September 2013].

2. Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.6). Available from: http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf [accessed 29 September 2013].

3. DR-TB drugs under the microscope: sources and prices for drug resistant TB medications. 2nd ed. Geneva: Médecins Sans Frontières & International Union Against Tuberculosis and Lung Disease; 2012.

4. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.;Ahuja;PLoS Med,2012

5. World Health Organization [Internet]. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva: WHO; 2013. Available from: http://www.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf [accessed 23 August 2013].

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatoprotective Effect of the Ursolic Acid-Oleanolic Acid Mixture Administered Intragastrically in Mice with Liver Damage Induced by Anti-TB Drugs;Qeios;2023-11-29

2. Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania;Pilot and Feasibility Studies;2023-04-01

3. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis;New England Journal of Medicine;2022-12-22

4. Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different;PLOS ONE;2022-07-25

5. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis;Trials;2022-06-13